Comparison of the perioperative time courses of matrix metalloproteinase-9 (MMP-9) and its inhibitor (TIMP-1) during carotid artery stenting (CAS) and carotid endarterectomy (CEA)

BMC Neurol. 2018 Aug 29;18(1):128. doi: 10.1186/s12883-018-1133-1.

Abstract

Background: Our aim was to compare the perioperative time courses of matrix metalloproteinase-9 (MMP-9) and its inhibitor (TIMP-1) in during carotid endarterectomy (CEA) and carotid artery stenting (CAS).

Methods: In our prospective study, twenty-five patients who were scheduled to undergo CAS were enrolled. We used a matched, historical CEA group as controls. Blood samples were collected at four time points: T1: preoperative; T2: 60 min after stent insertion; T3: first postoperative morning; and T4: third postoperative morning. Plasma MMP-9 and TIMP-1 levels were measured by ELISA.

Results: In the CEA group, the plasma levels of MMP-9 were significantly elevated at T3 compared to T1. In the CAS group, there was no significant difference in MMP-9 levels in the perioperative period. MMP-9 levels were significantly higher in the T3 samples of the CEA group compared to the CAS group. Significantly lower TIMP-1 levels were measured in both groups at T2 than at T1 in both groups. MMP-9/TIMP-1 at T3 was significantly higher than that at T1 in the CEA group compared to both T1 and the CAS group.

Conclusions: CAS triggers smaller changes in the MMP-9-TIMP-1 system during the perioperative period, which may correlate with a lower incidence of central nervous system complications. Additional studies as well as cognitive and functional surveys are warranted to determine the clinical relevance of our findings.

Trial registration: NIH U.S. National Library of Medicine, Clinicaltrials.gov,NCT03410576, 24.01.2018, Retrospectively registered.

Keywords: Carotid endarterectomy; Carotid stenting; MMP-9; Matrix metalloproteinase; TIMP-1.

Publication types

  • Comparative Study

MeSH terms

  • Aged
  • Carotid Stenosis / surgery*
  • Endarterectomy, Carotid* / adverse effects
  • Female
  • Humans
  • Incidence
  • Male
  • Matrix Metalloproteinase 9 / blood*
  • Middle Aged
  • Perioperative Period
  • Prospective Studies
  • Retrospective Studies
  • Stents
  • Time Factors
  • Tissue Inhibitor of Metalloproteinase-1 / blood*
  • Treatment Outcome
  • United States
  • Vascular Surgical Procedures / adverse effects

Substances

  • TIMP1 protein, human
  • Tissue Inhibitor of Metalloproteinase-1
  • MMP9 protein, human
  • Matrix Metalloproteinase 9

Associated data

  • ClinicalTrials.gov/NCT03410576